Warburg Pincus made a C$8.3 million (about $8.1 million) investment in Protox Therapeutics as part of a previously agreed investment deal signed in September 2010. The agreement gives Warburg ...

Kissei Pharamaceutical is paying Protox Therapeutics $3 million up front for exclusive Japanese rights to the latter’s Phase II PSA-activated prodrug, PRX302, for prostate-related diseases ...

Protox Therapeutics Inc <PRX.TO> said its experimental treatment for prostate enlargement showed continued efficacy after six months, but was not statistically significant, sending its shares down ...